Metrosert and South Korean partners to test AI health solution

TALLINN - A collaboration launched this spring between Estonia's Metrosert and South Korea's Gangwon Technopark is now moving into its first practical project. In partnership with technology company MENINBLOX, real-world validation will begin for Roopin, an AI-based solution designed to assess a runner's training load and recovery.

The project aims to evaluate the solution's performance among European users and prepare it for entry into the European Union market.

Roopin, developed by MENINBLOX, combines a user's running and injury history with data from their smartwatch, including activity levels, sleep efficiency, and heart rate variability. The solution's Ailix AI engine uses this information to assess the runner's daily condition and provide personalized recommendations on training load and rest. The application is designed to support users in making decisions about their training and recovery, not to provide a medical diagnosis.

The initial plan involves 50 Estonian amateur runners who will use the solution for four weeks. The validation will assess the application's usability, user adherence to training and rest recommendations, and how the AI's suggestions align with evaluations from independent sports medicine experts.

According to Metrosert board member Kaupo Reede, this is an exciting challenge that combines the evaluation of artificial intelligence models, the secure use of health data, and expertise in applied research.

"The health data division of Metrosert's applied research center was created specifically to enable companies to use health data for developing their products and services. We assist in designing studies and data flows, assessing data quality and AI model performance, and ensuring the secure processing of data," Reede said. "Our goal is to transform development work into reliable, evidence-based results that companies can use to build their business, both domestically and internationally."

According to MENINBLOX CEO Benjamin Park, entering the European market requires an independent assessment of the solution's performance in an environment that complies with European data protection and quality standards.

"In health technology, it's not enough for an AI to perform well in its home market; its effectiveness must also be evaluated with users from different backgrounds, with different habits and data. It is also crucial to ensure the transparent and secure use of health data," said Park. "As Estonia's national center for applied research, Metrosert provides us with the necessary independent expertise and a reliable validation framework. The results of this collaboration will help us further develop Roopin and prepare the solution for its European market entry."

The project is funded by the South Korean program 'Gangwon AI Healthcare Global Innovation Zone 2026.' The program aims to support the international development and market entry of AI-based health technologies developed in the Gangwon region.

AS Metrosert is Estonia's national applied research center and central authority for metrology. The state-owned company employs approximately 140 specialists and supports sustainable economic growth through applied research, measurement services, quality systems, and collaboration between industry and research institutions. The applied research center focuses on five key areas: drone technology, autonomous vehicles, hydrogen technology, biorefining, and health data.